使用阿加西酶 alfa 成功治疗了一名在使用阿加西酶 beta 后出现过敏性休克的法布里病患者：病例报告。

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL

Northern Clinics of Istanbul Pub Date : 2024-01-24 eCollection Date: 2024-01-01 DOI:10.14744/nci.2022.45656

Mehmet Erdem Cakmak

{"title":"使用阿加西酶 alfa 成功治疗了一名在使用阿加西酶 beta 后出现过敏性休克的法布里病患者：病例报告。","authors":"Mehmet Erdem Cakmak","doi":"10.14744/nci.2022.45656","DOIUrl":null,"url":null,"abstract":"Fabry disease is a rare genetic disease caused by a deficiency of α-galactosidase A gene (α-Gal A). Two intravenous enzymes administered every two weeks, agalsidase alfa and beta can slow disease progression and increase survival if administered early, before organ damage occurs. In this case report, we present a patient with a history of anaphylaxis to agalsidase beta who was successfully treated with agalsidase alfa.","PeriodicalId":19164,"journal":{"name":"Northern Clinics of Istanbul","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10861426/pdf/","citationCount":"0","resultStr":"{\"title\":\"Successful treatment using agalsidase alfa of a patient with Fabry disease who had anaphylaxis after agalsidase beta: A case report.\",\"authors\":\"Mehmet Erdem Cakmak\",\"doi\":\"10.14744/nci.2022.45656\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Fabry disease is a rare genetic disease caused by a deficiency of α-galactosidase A gene (α-Gal A). Two intravenous enzymes administered every two weeks, agalsidase alfa and beta can slow disease progression and increase survival if administered early, before organ damage occurs. In this case report, we present a patient with a history of anaphylaxis to agalsidase beta who was successfully treated with agalsidase alfa.\",\"PeriodicalId\":19164,\"journal\":{\"name\":\"Northern Clinics of Istanbul\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10861426/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Northern Clinics of Istanbul\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14744/nci.2022.45656\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Northern Clinics of Istanbul","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/nci.2022.45656","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

法布里病是一种因缺乏α-半乳糖苷酶A基因（α-Gal A）而引起的罕见遗传病。每两周静脉注射两种酶，即α-阿加糖苷酶和β-阿加糖苷酶，如果能在器官损伤发生之前及早用药，可延缓疾病进展并提高存活率。在本病例报告中，我们介绍了一位曾对阿加西酶 beta 过敏的患者，她成功地接受了阿加西酶 alfa 的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Successful treatment using agalsidase alfa of a patient with Fabry disease who had anaphylaxis after agalsidase beta: A case report.

Fabry disease is a rare genetic disease caused by a deficiency of α-galactosidase A gene (α-Gal A). Two intravenous enzymes administered every two weeks, agalsidase alfa and beta can slow disease progression and increase survival if administered early, before organ damage occurs. In this case report, we present a patient with a history of anaphylaxis to agalsidase beta who was successfully treated with agalsidase alfa.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Northern Clinics of Istanbul MEDICINE, GENERAL & INTERNAL-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

10 weeks